Do guidelines on the prevention of cardiovascular disease (CVD) improve the efficacy of preventive strategies in clinical practice? This question is relevant because, despite many efforts to improve the quality of preventive cardiology, results from surveys in different countries continue to show that many subjects receive no or inappropriate preventive care. 1, 2 Different approaches have been proposed and used in the past decades to improve preventive cardiology in clinical practice, such as:
. audit and feedback, . economic incentives, . organizational changes in health service delivery, . evidence-based guidelines.
The aim of the latter is to present and interpret all the relevant evidence on CVD prevention in order to help practitioners to weigh the benefits and risks of a particular diagnostic or therapeutic strategy; they should be helpful in daily clinical medical decision making.
In the field of CVD prevention, a great number of guidelines have been issued in recent years by different national and international organizations. This wealth of documents may harm the authority of guidelines, particularly if there are areas of disagreement. During the past 2 years, two major new guidelines related to the prevention of CVD have been issued in Europe. In 2011 the European Atherosclerosis Society and the European Society of Cardiology (ESC) issued for the first time joint guidelines for the management of dyslipidaemias. 3 In 2012 the Fifth Joint Task Force of European Societies on CVD prevention in clinical practice presented the fourth update of these guidelines dealing with prevention of CVD in general. 4 In the near future an update of the Joint European Society of Hypertension/ESC guidelines for the management of arterial hypertension is expected as well as an update of the guidelines on CVD prevention in patients with diabetes by a joint task force of the European Association for the Study of Diabetes and the ESC. The ultimate objective of all these guidelines is identical: to facilitate the prevention of CVD in all its clinical manifestations. Can this plethora of guidelines really be expected to improve the prevention of CVD and quality of care? Is it not unreasonable to expect busy practitioners to digest and implement so much information, often on top of a heavy clinical workload?
A crucial point in this respect is consistency of the recommendations and messages in these guidelines and hence their complementarity. Guidelines should be simple, straightforward, clear, and credible. Given the diversity that still exists between guidelines from different expert committees, we should aim at better harmonization with a focus on arriving at consensus on matters of practical importance rather than on endless debate about the minutiae of basic science.
Furthermore, guidelines are just a help to informed decision making and not commandments carved in stone; national societies should be strongly encouraged to ask local task forces or working groups to examine these guidelines on CVD prevention to see if they should be adapted to suit local socioeconomic and cultural issues. This is particularly the case for the healtheconomic aspects, which are not considered in the European guidelines because of the considerable heterogeneity between European countries in terms of healthcare systems and structure as well as healthcare expenditures.
Other conditions that should be fulfilled for having guidelines accepted and implemented are not specific for guidelines on prevention; they relate to validity, reproducibility, reliability, applicability, flexibility, clarity but also to the question on how the evidence has been collected and this may require some different approaches; different questions require different scientific methods. Practical derivative educational products such as pocket and PDA versions, essential messages, or slide sets are also of great help, make the messages more concise and easy to use.
The quality of the evidence ultimately depends on the questions to be answered. The criteria will be different, for example, for diagnostic tests, risk estimation, or the evaluation of treatments, an aspect that is not adequately reflected in either the current ESC or American Heart Association (AHA) systems of grading evidence. In the most recent European guidelines on CVD prevention, the Joint Task Force has attempted to ensure that the most appropriate evidence was used to underpin recommendations. In examining the effects of lifestyle changes and in the absence of randomized controlled trials (RCTs), prominence has been given to systematic reviews of observational studies such as the Cochrane reviews.
Both the ESC and the AHA favour a grading system where the level of evidence and the strength of the recommendation of particular treatment options are weighed and graded according to predefined scales. At the population level, prevention of CVD largely depends on lifestyle adaptations and RCTs with ''hard'' CV endpoints are for ethical and logistic reasons not possible for these lifestyle measures. Smoking cessation, exercise, and healthy eating are less amenable to RCTs than are drug therapies and too strict adherence to the primacy of RCTs may result in guidelines that promote excessive usage of drugs.
Other grading systems may be more appropriate for guidelines on prevention. One of them might be the Grading of Recommendations Assessment, Development and Evaluation or GRADE system 5 which uses a transparent and rigorous process to assess the quality of evidence. With the GRADE system the judgment is made on quality of evidence for the critical outcomes that will guide decision making. With this system, the evidence based on results from RCTs can be downgraded when these quality criteria are poor; similarly the evidence based on results from observational studies can be upgraded if the findings are consistent and accurate.
Another issue related to grading is to distinguish between the quality of the evidence and the strength of a recommendation underpinned by the evidence. Not all high quality evidence merits a strong recommendation and vice versa. Recommendations, in fact, are based on the quality of the evidence but also on the degree of uncertainty about the balance of benefits and harms of intervention, uncertainty about the values and preferences of the patients and uncertainty about whether the intervention is a wise use of resources. Rather than have a range of classes of recommendations, GRADE only uses two categories: strong or weak recommendation. The GRADE system has been used for the first time in the most recent upgrade of the Joint European Societies' Task Force on CVD prevention.
Not only is the grading system of guidelines on CVD prevention problematic but one would reasonably wish for more uniformity between guidelines in assessing total CV risk, in stratifying the asymptomatic population in different risk categories and in setting target values for the different risk factors to address. Different approaches are likely to generate confusion.
The development of guidelines is not a simple or an easy endeavour. Guidelines for the development of guidelines are now available (www.escardio.org/knowledge/guidelines/rules) and if these are not taken into consideration the authority and credibility of guidelines can be jeopardized, leading to confusion and eventually rejection. In reading and comparing the guidelines on dyslipidaemias and on prevention in general it is reassuring to see that great attention was paid to consistency and complementarity; appropriately, the lipid guidelines go into much more detail with regard to the finer aspects of lipid management but the starting point (risk assessment and stratification) and the target values are the same as those recommended in the general prevention guidelines. This is an example on how to proceed among different partners involved in the prevention of CVD and producing guidelines.
In summary, the focus should be on areas of agreement with regard to major issues rather than debate on minutiae, while allowing flexibility to accommodate new knowledge. We need to listen to the clinicians who ask for comprehensible, readily accessible, and practical advice and when delivering such guidelines to them we have to speak with one voice. 6 
